Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Ipsen is a specialty pharmaceutical company that develops and sells medicines for cancer, neurological disorders, and rare diseases.
Ipsen is a French drugmaker that focuses on a few specific areas of medicine rather than trying to be everything to everyone. It sells treatments for cancer, for neurological conditions, and for rare diseases, mostly to hospitals and specialists around the world rather than through ordinary pharmacies.
Its roots go back to 1929, when a French pharmacist named Henri Beaufour founded a small family lab in Paris. The company stayed in the Beaufour family's hands for decades and grew through a series of acquisitions before going public on the Paris exchange in 2005. That family heritage still shapes it: Ipsen has kept a reputation as a nimble specialist rather than a giant, with a few blockbuster franchises carrying a lot of the weight. The most important of those franchises is a group of cancer drugs sold under the Somatuline and Cabometyx brands, widely used in neuroendocrine tumors and kidney cancer. Alongside them, Ipsen sells Botox — yes, the same brand used in cosmetic clinics — for medical uses like muscle spasticity and movement disorders, a quieter but steady business. Rare-disease treatments, including bile-acid medicines for liver conditions, round out the portfolio. That mix of big cancer sellers and steady specialty drugs is why Ipsen can spend heavily on research and still return cash to shareholders through dividends and occasional buybacks.
Ipsen's strengths are its focus and its pricing power in small, specialized markets where competition is thin. The risk is that a big share of revenue leans on a handful of drugs, so a patent cliff or a failed trial can hurt quickly. It has been busy buying and partnering to refill its pipeline, including a multi-billion-dollar deal for the rare-disease specialist Albireo and cancer assets from Merck. For investors, the simple case is: a mid-sized French specialist with profitable franchises, good cash flow, and a need to keep finding the next big medicine.
Saved answer · last researched 15 Nov 2026